Authera Is A Pre Clinical Stage Biotechnology Company Founded In 2022Emerging From Oslo University Hospital And The University Of Oslothe Company Specializes In Molecular Design And Protein Engineering To Create Novel Therapeutic Biologicsfocusing On The Neonatal Fc Receptorfcrn Which Plays A Key Role In Regulating The Lifespan Of Igg Antibodies And Albumin In The Bloodstream Authera Utilizes A Proprietary Platform That Combines Biochemicalcellularand In Vivo Models To Design Molecules With Specific Fcrn Binding Propertiesthis Innovative Approach Aims To Enhance Therapeutic Efficacy And Minimize Development Risksthe Company S Lead Candidateaut 1Is In Pre Clinical Development And Targets Exudative Eye Diseasesauthera Is Committed To Advancing Its Internal Pipeline While Fostering Science Driven Collaborations With Academic Institutionsbiotech Firmsand Pharmaceutical Partners
